Novorex is a specialized company focused on the development of new small molecule drugs, primarily targeting oncology and neurology diseases. The company employs Fragment-based Drug Discovery (FBDD) as a core technology, which allows for the identification and optimization of drug candidates through the analysis of small chemical fragments. This method is complemented by the use of artificial intelligence, enabling Novorex to enhance the efficiency and effectiveness of the drug discovery process. By integrating these advanced technologies, Novorex aims to streamline the entire drug development pipeline, from initial design to final testing.

In addition to FBDD, Novorex emphasizes a seamless drug discovery approach that incorporates biophysical analysis and both in vitro and in vivo assays. This comprehensive strategy is designed to ensure that the new drugs developed are not only innovative but also exhibit high efficacy. The collaboration with pharmaceutical experts further strengthens Novorex's capabilities, allowing the company to leverage extensive industry knowledge and experience in the pursuit of groundbreaking treatments for complex diseases.

South Korea

Novorex is specialized company in the development of new small molecule drugs targeting mostly oncology and neurology diseases using FBDD and artificial intelligence with pharmaceutical experts.
Seamless Drug Discovery is performed using cutting-edge technology that considers the entire process of new drug development.
We aim to develop high-efficiency new drugs through drug design that combines biophysical analysis and in vitro/in vivo assay.

240 Pangyoyeok-ro, #302 Samhwan HIPEX A, Bundang-gu, Seongnam-si, Gyeonggi-do, KR

Novorex

Company Details